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Abstract The purpose of the study was to analyse the
inﬂuence of HPV infection on the outcome of a random-
ized clinical trial of conventional (CF) versus 7-days-
a-week postoperative radiotherapy (p-CAIR) for squamous
cell cancer of the head and neck (SCCHN). Between 2001
and 2004, 279 patients with high-risk SCC of the larynx or
cancer of the oral cavity/oropharynx were randomized to
receive 63 Gy in fractions of 1.8 Gy given 5 days a week
or 7 days a week (Radiother Oncol 87:155–163, 2008). The
presence of HPV DNA in 131 archival parafﬁn blocks was
assessed with multiplex quantitative real-time PCR using
ﬁve consensus primers for the conservative L1 region and
molecular beacon probes targeting 14 high-risk HPV sub-
types. Following the RT-PCR procedure, we could deter-
mine the presence and type of HPV16, HPV18 and the
other 12 less frequent oncogenic subtypes. Out of 131
samples, 9 were positive for HPV infection (6.9%), all of
them with HPV16 subtype. None of the 65 laryngeal
tumours was HPV positive. The 5-year LRC in HPV-
positive patients was 100%, compared to 58% in the HPV-
negative group (p = 0.02, log-rank test). Amongst 122
patients with HPV-negative tumours, 5-year LRC was
50.3% in p-CF versus 65.2 in p-CAIR (p = 0.37). HPV
infection was associated with low expression of EGFR and
cyclin D. This study demonstrates a favourable outcome
for HPV-positive patients with SCCHN treated with post-
operative radiotherapy. While considering the small num-
ber of HPV? tumours, the data set can be considered as
hypothesis generating only, the outcome raises new ques-
tions on the necessity of aggressive postoperative treatment
in HPV? patients.
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Introduction
Several recent studies have shown that HPV-positive
squamous cell cancer of the head and neck (SCCHN) has
different clinical and histological characteristics and better
prognosis than HPV-negative tumours [1–4]. The prog-
nostic potential of HPV infection with distinct reference to
postoperative radiotherapy has been, however, less
frequently addressed. Also, the incidence of HPV infection
appears dissimilar in diverse regions of the world and,
apparently, changes over time, thus providing background
for further research [5, 6]. This prompted us to analyse the
HPV infection status of tumour samples obtained from
participants of a recently conducted randomized trial on
conventional versus accelerated 7-days-a-week postopera-
tive radiotherapy [7] and assess the impact of HPV
infection on the outcome of the trial.
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Clinical background of the study
The p-CAIR trial was performed between 2001 and 2004,
and recruited 279 patients with high-risk squamous cell
cancer of the larynx (158 patients) or cancer of the oral
cavity/oropharynx (121 patients). Clinical characteristics of
the whole group of 279 patients, a detailed presentation of
the risk assessment scale, treatment description and the
clinical outcome have been presented elsewhere [7].
Importantly, the patients were randomized to receive
63 Gy in fractions of 1.8 Gy given either 5 days a week
(140 patients, p-CF: postoperative conventional fraction-
ation) or 7 days a week (139 patients, p-CAIR: postoper-
ative continuous accelerated irradiation).
Recently, we have presented an analysis of the immu-
nohistochemically assessed expression of ﬁve molecular
markers (EGFR, nm23, Ki-67, p53 and cyclin D1) in
relation to the outcome of the trial. Of the 279 patients who
were enrolled, it was possible to obtain data for the
molecular studies on 148 patients [8]. The emerging data
on the importance of HPV infection on the outcome of
radiotherapy for SCCHN prompted us to expand the
analysis and evaluate HPV status in the remaining portions
of tumours embedded in parafﬁn blocks. The follow-up
data have been updated in the present study and show the
status of the patients as of January 2010. We note that the
update does not affect the qualitative outcome of
the analysis, because new loco-regional recurrences have
not been recorded since the last publication.
Characteristics of the patients
Out of 148 parafﬁn blocks used in the earlier study [8], it
was possible to assess HPV infection status in 131 patients.
In ten patients no remaining tumour tissue was present in
the blocks and in seven the material was of insufﬁcient
quality to get informative PCR results. Table 1 presents the
clinical characteristics of 131 patients included in the
analysis. The general characteristics of the subgroup ana-
lysed in the present study did not differ considerably from
that of the population of 279 patients. Importantly, the risk
factors for recurrence were evenly distributed between the
trial arms. The actual mean overall radiation treatment time
amongst 131 patients was 49.0 days (SD ±3.6) in CF
versus 35.6 (SD ±7.2) in p-CAIR. Two patients in p-CF
and four in p-CAIR received total radiation doses lower
than planned, due to deteriorating general performance
before or during radiotherapy. Three patients in p-CF
received total doses higher than in the protocol due to
local/nodal tumour progression during treatment or treat-
ment planning. One patient in p-CAIR arm died before
radiotherapy was started. The other 121 patients received
63 Gy in 1.8 Gy fractions. None of the patients received
chemotherapy. The analysis, as shown, was performed on
intention-to-treat basis.
The analysis of HPV status
Detection of HPV DNA in parafﬁn-embedded tumour
histopathological samples was made using RealTime High
Risk HPV test (Abbott Molecular). It is a qualitative test
that can detect 14 high-risk HPV types in the same reac-
tion. It can differentiate between HPV16, HPV18 and other
less frequent HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68). The HPV target sequence is located in the
conserved L1 region of the viral genome. The reaction mix
contained three forward and two reverse primers designed
to hybridize to an approximately 150-base HPV consensus
region. A pair of primers targeting 136 bases in the human
b-globin gene, serving as an internal control, was also
included. Detection of ampliﬁcation products was achieved
with the aid of 15 distinct ﬂuorescently labeled probes.
The laboratory procedure consisted of three steps: DNA
isolation, reaction assembly and real-time PCR. DNA was
isolated from archival parafﬁn-embedded tumour samples.
For each sample, ten 10-lm thick sections were collected
in an aseptic manner. They were deparafﬁnized, rehydrated
and digested in two changes of xylene, graded alcohols and
Proteinase K 100 lg/ml (Sigma–Aldrich) for 24 h at 56C,
respectively. Next, samples were processed using mSample
Preparation SystemDNA (Abbott Molecular) where DNA
was immobilized on the surface of magnetic microparti-
cles, puriﬁed and eluted ready for ampliﬁcation. The DNA
purity and concentration were evaluated with Nanodrop
Table 1 Characteristics of 131 patients analysed in the present study
p-CF (N = 64) p-CAIR (N = 67)
Age (median, range) 59 (39–71) 57 (41–77)
Gender F: 6 (9.3%) F: 9 (13.4%)
M: 58 (90.7%) M: 58 (86.6%)
T T1, T2: 17 (26.6%) T1, T2: 17 (25.3%)
T3, T4: 47 (73.4%) T3, T4: 57 (74.7%)
N N0: 23 (35.9%) N0: 17 (25.4%)
N?: 41 (64.1%) N?: 50 (74.6%)
Tumour site Larynx: 31 (48.4%) Larynx: 34 (50.7%)
Other: 33 (51.6%) Other: 30 (49.3%)
Margins Neg.: 34 (53.1%) Neg.: 42 (62.7%)
Pos.: 19 (29.7%) Pos.: 21 (31.3%)
Uncertain: 11 (17.2%) Uncertain: 4 (6.0%)
Grade G1: 14 (21.9%) G1: 10 (14.9%)
G2: 35 (54.7%) G2: 38 (56.7%)
G3: 15 (23.4%) G3: 19 (28.4%)
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123ND-1000 spectrophotometer. On completion of sample
preparation, an ampliﬁcation master mix was prepared with
AmpliTaq Gold, MgCl2 solution and oligonucleotide
reagent containing primers, probes and dNTPs. The PCR
reaction was then assembled in 96-well optical reaction
plate by combining 25 ll of master mix and 400 ng of
extracted DNA diluted to a ﬁnal volume of 25 ll with
molecular biology-grade puriﬁed water (Water Mol Biol
grade DNase RNase and Protease-free, 5Prime). Thermo-
cycling and products detection were carried out in the
m2000rt real-time PCR instrument (Abbott Molecular,
system based on Applied Biosystems Inc. RT7500
thermocycler).
Negative and positive controls were included in each run
to verify that sample processing, ampliﬁcation and detec-
tion steps were performed correctly. The negative control
was formulated with DNA containing b-globin sequence
and poly-dA:dT as carrier DNA. The positive control
contained HPV16, HPV18, HPV58 and b-globin sequences
tied to the carrier DNA.
Samples were considered to be positive when Ct value
for any of the detected HPV type and b-globin was less or
equal to the cutoff value of 35. Samples for which b-globin
Ct value was[35 were considered to be non-informative.
Statistical analysis
Loco-regional failure was deﬁned as the recurrence of
cancer at the primary tumour site, within the neck or
supraclavicular nodes, and distant metastases as recurrence
elsewhere. Survival curves were plotted using Kaplan–
Meier method and compared using log-rank test.
Results
HPV status versus clinical outcome
HPV DNA was detected in 9 out of 131 tumour samples
(6.9%). In all nine cases, HPV 16 subtype was found.
Figure 1 shows the ﬂow diagram of the cases assessed for
HPV infections, including reference to the primary tumour
site. HPV was not detected in any of the 65 patients with
cancer of the larynx or hypopharynx, compared to 9/66
(13.6%) HPV? cases amongst patients with cancer of the
oral cavity or oropharynx. Out of 11 patients with cancer of
the tonsil, there were 6 HPV? tumours (54.5%). The other
HPV? tumours included two cancers of the base of tongue
and one with cancer of the retromolar triangle. There were
no signiﬁcant differences in patients’ age between the
HPV? and HPV- groups (median age, 59 vs. 57 years,
respectively).
Five patients with HPV? tumours were treated with
p-CF, and four with p-CAIR. Figure 2a shows loco-regio-
nal tumour control according to HPV status irrespective of
fractionation. The 5-year loco-regional tumour control was
100% in HPV? cases, compared to 58% in HPV- cases
(p = 0.02, log-rank test). Amongst 122 patients with
HPV- tumours, 5-year LRC was 50.3% in p-CF versus
65.2 in p-CAIR (p = 0.37, Fig. 3).
Randomized (n=279) 
Not available (131 samples)
(17 samples)  
Analysed cases (n=131), HPV(+):  9/131 (6.9%) 
       Available samples (n=148) 
No tumor/poor quality  
       Oropharynx/oral cavity (n=66) Larynx/hypopharynx (n=65) 
HPV(+): 9/66 (13.6%)    HPV(+): 0/65 (0 %) 
  Tonsil (n=11)  Base of tongue  (n=5)                        Other (n=50)  
HPV(+): 6/11 (54.5%)       HPV(+): 2/5 (40.0%)                    HPV(+): 1/50 (2.0%)         
Fig. 1 Flow diagram of the
cases assessed for HPV
infections
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123None of the nine patients with HPV? tumours devel-
oped distant metastases. Five-year distant metastases-free
survival in the HPV- group was 82% (Fig. 2b). Two out of
nine patients with HPV? tumours (22.2%) developed
metachronous second cancer (bladder cancer and colorectal
cancer) compared to 10/122 (8.2%) in the HPV- group.
HPV infection versus expression of selected molecular
markers
Using the data from previously published study on
molecular markers [8], it was possible to assess the rela-
tionship between HPV infection and immunohistochemi-
cally assessed expression of EGFR, nm23, Ki-67, p53 and
cyclin D1.
Out of nine HPV? tumours only one (11%) had high
expression of EGFR (more than 33% of the cells stained)
compared to 32% in the HPV- group. Also, out of nine
HPV? tumours, only one (11%) had high expression of
cyciln D, compared to 29% in the HPV- group.
No apparent differences in expression of nm23, Ki-67 or
p53 were found between HPV? and HPV- tumours.
Discussion
Prevalence of HPV infection
Perhaps, the most noticeable result that comes from the
present study is that the overall prevalence of HPV infec-
tion was low amongst patients enrolled to the p-CAIR trial,
at least compared to other recently published studies on this
subject [1–3]. Several factors may explain such charac-
teristics of the present group.
The dissimilar rate of infection worldwide is an
important factor. In general, the prevalence of HPV in
SCCHN is lower in Europe, compared to North America or
Asia [5]. Behavioural differences, especially those related
to smoking, alcohol consumption, practice of oral sex and
number of lifetime sexual partners, may explain the
apparent diversity [9]. The majority of patients in the
p-CAIR trial inhabited mostly underprivileged, heavily
industrialized Upper Silesia region in Poland, characterized
by a conservative lifestyle, and high tobacco and alcohol
consumption. Such communal characteristics would pre-
dispose to HPV-unrelated cancer. Interestingly, the age of
patients with HPV? tumours did not differ from that of the
HPV- group in the present study, contrary to many other
studies in which HPV-related tumours were detected at a
relatively young age [5]. A substantial proportion of
patients with cancer of the larynx in the analysed group
(65/131, 49.6%) may further contribute to the low preva-
lence of HPV infection, because HPV? is more frequent
amongst patients with cancer of the oropharynx compared
to the larynx. Another factor that contributed to low HPV
infection rate was, likely, the selection for p-CAIR trial that
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Fig. 2 Loco-regional tumour control (a) and metastases-free survival
(b) according to HPV infection in 131 patients from p-CAIR trial
(irrespective of fractionation)
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Fig. 3 Loco-regional tumour control according to fractionation in
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123accumulated high-risk patients. Also, the prevalence of
HPV infection has a propensity to increase with time [6],
and would be, likely, higher at present, compared to
patients treated between 2001 and 2004. Also, diverse
methodological approaches in the assessment of HPV
infection may contribute to diversity in the reported prev-
alence of infection. Most notably, setting different cutoffs
for Ct value for any of the detected HPV type and b-globin
would affect the detection rate.
HPV infection and the outcome of postoperative
radiotherapy
Several studies demonstrated that amongst patients with
SCCHN, those with HPV? tumours had a better prognosis
than those with HPV- [1–5]. Most of these studies, how-
ever, referred to radiotherapy or radiochemotherapy, while
the impact of HPV infection on the outcome of postoper-
ative treatment has been less frequently discussed. A small
number of HPV? tumours in the present series preclude
deﬁnitive conclusions, and the data set can only be used as
hypothesis generating. The analysis, nevertheless, suggests
that both loco-regional control and metastases-free survival
are excellent amongst HPV? tumours treated with
postoperative radiotherapy, though these tumours were
originally considered to be at high risk for recurrence
according to traditional pathological criteria. Neither loco-
regional failures nor distant metastases were observed in
long-term follow-up amongst nine individuals with HPV?
tumours irrespective of fractionation. This raises new
questions about the necessity of aggressive adjuvant post-
operative treatment in HPV? patients, providing the back-
ground for further research. Likewise, a favourable outcome
amongst HPV? tumours may raise questions about new
strategies for organ preservation [10]. Clearly, the response
tothesequestionsmustbe addressedin the analysis oflarger
data sets of HPV? tumours. Also, due to small sample size,
the relevance of fractionation in HPV? tumours cannot be
addressed in the present study. Conversely, however, more
insight can be gained regarding HPV- tumours, which
represented the majority of the analysed cases. Figure 3
illustrates that loco-regional control in HPV- tumours was
improved by p-CAIR, butthe difference did notappear tobe
signiﬁcant(p = 0.37).Thequalitativeoutcomeofthetrialin
theHPV-subsetappeared,thus,similartothatobtainedina
whole data set of 279 patients [7].
An interesting observation was the detection of two
metachronous malignant tumours amongst nine individuals
with HPV? tumours. The rate of synchronous and
metachronous lesions in HPV-positive SCCHN is, at
present, largely unknown. Some case reports suggest
increased susceptibility of patients with HPV? tumours to
synchronous tumours [11, 12]. Other studies suggest,
however, lower incidence of metachronous tumours in
HPV? cases [13].
HPV infection versus expression of selected molecular
markers
Several studies have shown overexpression of p16 in
HPV? tumours, and some of them suggested the potential
role of this marker as a surrogate for HPV infection [14,
15]. The relationship between HPV infection and expres-
sion of the other markers has been also investigated in
these studies. While a small number of HPV? tumours in
the present data set preclude statistically meaningful
conclusions,the analysis supports studies showingthat HPV
infection is associated with low expression of EGFR and
cyclin D in tumour cells [14, 15]. Differences in expression
of molecular markers in HPV? and HPV- tumours provide
additional support for the existence of two distinct carcino-
genetic pathways for the development of HNSCC: one
driven by carcinogenic effects of tobacco or alcohol and
another by HPV-induced cell cycle dysregulation.
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